Search company, investor...
Search

Predict your next investment

China Merchants Capital company logo
Asset/Investment Management
FINANCE | Asset/Financial Management
cmcapital.com.cn

See what CB Insights has to offer

Investments

122

Portfolio Exits

13

Funds

8

About China Merchants Capital

China Merchants Capital is a subsidiary of China Merchants Group in Hong Kong, specializing in alternative investment and asset management, the Group's investment management and business development platform, and actively explore the market, constantly cultivate new industries, to enhance the vitality of capital; on the other hand, the integration of the Group's internal resources, finance and industry to promote the combination of each other. By the end of 2015, China Merchants Capital Managed assets of nearly 33 billion yuan(RMB).

China Merchants Capital Headquarters Location

20/F Tower B, East Pacific International Center 7888 Shennan Avenue, Futian District

Shenzhen, Guangdong, 518040,

China

+86 755 88326300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

China Merchants Capital Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

China Merchants Capital Rank

Latest China Merchants Capital News

Porton Advanced Completes Series B Financing Round

Aug 26, 2022

The proceeds will be used to expand the company’s end-to-end gene and cell therapy platforms. 08.26.22   The round of financing was led by China Merchants Groups' healthcare PE fund Merchant Health, along with its sister fund China Merchants Capital, China Merchants Securities Investments. In addition, a number of renowned venture and private equity firms participated in the current round of financing, including Fosun Health Capital, Gortune Investment and SDICTK. Apart from the new investors, current Porton Advanced shareholders, Porton Pharma Solutions, CS Capital, HM Capital, Ruilian Investment and Momentum Venture, also participated in the current round. Porton Advanced will use the proceeds to continue its business expansion into different markets, with investment in core manufacturing infrastructures and in global commercial operations. Such expansion would put Porton Advanced in a great position to become a global end-to-end gene and cell therapy (GCT) CDMO platform to help bring cutting edge therapies to patients. Focusing solely on gene and cell therapy CDMO services, Porton Advanced has rapidly established an integrated CDMO platform providing a spectrum of services covering plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and microbial vectors used for gene therapy (MVGTs). Current operational footprint includes a 40,000sqft R&D and GMP production facility already in operation for over two years, which successfully delivered a number of plasmids, viruses and cell batches to our sponsors. A 160,000 sq. ft facility for commercial production will be operational in the end of 2022/early 2023. By then, Porton Advanced will have over 200,000 sq. ft of PD, AD, and GMP manufacturing facility dedicated for gene and cell therapy. In total, Porton Advanced will have 10 GMP viral vector production lines, 10 GMP cell therapy production lines and hundreds of clean rooms. Such a scale and footprint would allow Porton Advanced to significantly upgrade its AAV, oncolytic virus and mRNA CDMO capacity and capability which in turn empower our sponsors and support the GCT industry. The current round of financing will also help Porton Advanced to further improve the development and manufacturing capacity in both China and overseas, with the aim of establishing a global end-to-end gene and cell therapy CDMO platform. Through its efforts to accelerate the development of GCT therapeutics, Porton Advanced intends to become a top player that help drive the transformation of medicine. Dr. Wang Yangzhou, CEO of Porton Advanced, said, "We are very pleased and grateful for the recognition and trust by China Merchants Health and all the other new and current capital partners. With a talented and passionate team, proprietary technologies, state of the art production lines and equipment, as well as track records from both Porton Advanced and from our parent company, Porton Pharma Solutions, we will work hand in hand with our sponsors and partners to reach more milestones in the GCT field. In the coming months, we will continue to improve and optimize our internal quality and program management systems, enhance our ability to operate at overseas and domestic markets, and continue to provide best possible CDMO services to our customers with our open, innovative and reliable platforms, so that best medicine would reach the public sooner." Trending

China Merchants Capital Investments

122 Investments

China Merchants Capital has made 122 investments. Their latest investment was in Porton Biologics as part of their Series B on August 8, 2022.

CBI Logo

China Merchants Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/22/2022

Series B

Porton Biologics

Yes

3

8/21/2022

Series B

Porton Advanced

$80M

Yes

1

8/18/2022

Series D

Reconova Technologies

Yes

1

8/2/2022

Series A

Subscribe to see more

Subscribe to see more

10

6/30/2022

Series D - II

Subscribe to see more

Subscribe to see more

10

Date

8/22/2022

8/21/2022

8/18/2022

8/2/2022

6/30/2022

Round

Series B

Series B

Series D

Series A

Series D - II

Company

Porton Biologics

Porton Advanced

Reconova Technologies

Subscribe to see more

Subscribe to see more

Amount

$80M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

1

1

10

10

China Merchants Capital Portfolio Exits

13 Portfolio Exits

China Merchants Capital has 13 portfolio exits. Their latest portfolio exit was Hongjiu Fruit on September 05, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/5/2022

IPO

$99M

Public

1

8/18/2022

IPO

$99M

Public

1

7/15/2022

IPO

$99M

Public

1

6/14/2022

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

11/12/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/5/2022

8/18/2022

7/15/2022

6/14/2022

11/12/2021

Exit

IPO

IPO

IPO

Reverse Merger

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Public

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

China Merchants Capital Acquisitions

1 Acquisition

China Merchants Capital acquired 1 company. Their latest acquisition was Terminal de Conteineres de Paranagua on August 28, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/28/2017

Private Equity

$99M

Corporate Majority

4

Date

8/28/2017

Investment Stage

Private Equity

Companies

Valuation

$99M

Total Funding

Note

Corporate Majority

Sources

4

China Merchants Capital Fund History

8 Fund Histories

China Merchants Capital has 8 funds, including Propertylink Australian Logistics Trust II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/19/2019

Propertylink Australian Logistics Trust II

$240.48M

1

5/15/2015

CMH Growth Fund

Subscribe to see more

Subscribe to see more

$99M

10

中垦基金 (China Reclamation Fund)

0

服务贸易创新发展引导基金 (Service and Trade Innovation Development Guidance Fund)

10

Shenzhen Zhaoshang Qihang Capital Enterprise LP

Subscribe to see more

Subscribe to see more

10

Closing Date

6/19/2019

5/15/2015

Fund

Propertylink Australian Logistics Trust II

CMH Growth Fund

中垦基金 (China Reclamation Fund)

服务贸易创新发展引导基金 (Service and Trade Innovation Development Guidance Fund)

Shenzhen Zhaoshang Qihang Capital Enterprise LP

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$240.48M

$99M

Sources

1

10

0

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.